Compile Data Set for Download or QSAR
Report error Found 512 Enz. Inhib. hit(s) with all data for entry = 11949
TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664519((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664524(US20240109930, Example 2.1.74.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664546(US20240109930, Example 2.1.89.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664585((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664432(US20240109930, Example 1.1.19. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664436(US20240109930, Example 1.1.23. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664450(US20240109930, Example 2.1.13. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664462(US20240109930, Example 2.1.23. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664483((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664491((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664509((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664510((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664511((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664518((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664520(US20240109930, Example 2.1.68.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664529((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664532(US20240109930, Example 2.1.78.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664534((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664537(US20240109930, Example 2.1.80.A | US20240109930, E...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664546(US20240109930, Example 2.1.89.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664549((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664557(US20240109930, Example 3.1.66.C | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664562((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664572((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664577((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664580((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664592((2R,3R,4S,5R,6R)-6-((1-(3-(difluoromethyl)oxetan- ...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664595((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664596((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664598((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664617(US20240109930, Example 1.2.37. | tert-butyl (4-(1-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664426(US20240109930, Example 1.1.13. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664428(US20240109930, Example 1.1.15. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664440(US20240109930, Example 1.1.27. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664446(US20240109930, Example 2.1.8. | (2R,3R,4S,5R,6R)-4...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664466(US20240109930, Example 2.1.27. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664477(US20240109930, Example 3.1.27. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664492((2R,3R,4S,5R,6R)-6-((1-(2-oxabicyclo[2.1.1]hexan-4...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664493((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664496((2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664504((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664513((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664516((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664517((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664520(US20240109930, Example 2.1.68.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664530(US20240109930, Example 2.1.77.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664530(US20240109930, Example 2.1.77.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664535((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664537(US20240109930, Example 2.1.80.A | US20240109930, E...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM664542(US20240109930, Example 2.1.88.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 512 total ) | Next | Last >>
Jump to: